Literature DB >> 12370834

Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells.

Nesrin M Hamad1, Soma S R Banik, Christopher M Counter.   

Abstract

A hallmark of cancer cells is the ability to proliferate indefinitely. This acquisition of an immortal lifespan usually requires the activation of telomerase, the enzyme that elongates telomeres. Human telomerase is minimally composed of the reverse transcriptase subunit hTERT, and the RNA subunit hTR. While hTR is ubiquitously expressed in human cells, the hTERT subunit is generally transcriptionally repressed in most normal somatic cells, but is illegitimately activated to restore telomerase activity in cancer cells. Indeed, in the thousands of different human tumours assayed, 85% were scored positive for telomerase activity. However, the levels of telomerase activity detected in tumour samples can vary substantially and even some normal somatic cells have been found to have low levels of enzyme activity. As the functional significance of low levels of telomerase activity is unclear, we investigated whether there is a minimum level of telomerase activity required for tumourigenesis. Using mutants of hTERT that induce varying levels of telomerase activity, we show that there does indeed exist a threshold of activity required for the processes of immortalization, transformation and tumourigenesis. Thus, low levels of activity detected in certain somatic cells would not be expected to contribute to tumourigenesis, nor does the mere detection of telomerase in cancer cells necessarily signify an immortal lifespan.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370834     DOI: 10.1038/sj.onc.1205860

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Chromosomal stability during ex vivo expansion of UCB CD34(+) cells.

Authors:  J Ge; H Cai; W S Tan
Journal:  Cell Prolif       Date:  2011-10-04       Impact factor: 6.831

2.  The minimal set of genetic alterations required for conversion of primary human fibroblasts to cancer cells in the subrenal capsule assay.

Authors:  Beicheng Sun; Meizhen Chen; Christina L Hawks; Olivia M Pereira-Smith; Peter J Hornsby
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

3.  The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells.

Authors:  Alessandra Rossi; Giuseppe Russo; Andrew Puca; Raffaele La Montagna; Mariella Caputo; Eliseo Mattioli; Massimo Lopez; Antonio Giordano; Francesca Pentimalli
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

4.  Telomerase activity and genetic alterations in primary breast carcinomas.

Authors:  Anna Papadopoulou; Theoni Trangas; Manuel R Teixeira; Sverre Heim; Euthimios Dimitriadis; Haroula Tsarouha; Johan A Andersen; Evangelos Evangelou; Panayiotis Ioannidis; Niki J Agnantis; Nikos Pandis
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

5.  Overexpression of Telomerase Protects Human and Murine Lung Epithelial Cells from Fas- and Bleomycin-Induced Apoptosis via FLIP Upregulation.

Authors:  Nissim Arish; Pazit Y Cohen; Regina Golan-Gerstl; Zvi Fridlender; Mark Richter Dayan; Philip Zisman; Raphael Breuer; Shulamit B Wallach-Dayan
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

6.  A translocation-defective telomerase with low levels of activity and processivity stabilizes short telomeres and confers immortalization.

Authors:  Yasmin D'Souza; Tsz Wai Chu; Chantal Autexier
Journal:  Mol Biol Cell       Date:  2013-02-27       Impact factor: 4.138

7.  Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.

Authors:  Jennifer L Elderbroom; Jennifer J Huang; Catherine E Gatza; Jian Chen; Tam How; Mark Starr; Andrew B Nixon; Gerard C Blobe
Journal:  Mol Biol Cell       Date:  2014-06-25       Impact factor: 4.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.